Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gentulizumab in Relapsed/Refractory AML or MDS
NCT05263271Phase 1Terminated
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Primary completion
- Dec 2024
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gentulizumab in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd. Primary endpoints: Adverse Events at 90 days and Serious Adverse Events at 90 days. Started Apr 2021; status: terminated.
02
Drugs
gentulizumab
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT05263271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05263271.